Analyst Consensus ?
ConsensusBuy12 ratings
Bullish975.0%
Neutral216.7%
Bearish18.3%
Solventum Corporation · SOLV · FY2026 Q2 · Calendar Q3 2026
Solventum raises guidance as ERP transition nears completion
The supplied analysis supports a constructive but conditional view of Solventum's operating trajectory: strong Q2 execution, raised guidance, Acera's growth, and progress on the 3M separation support the case for earnings growth and resilient demand. The case still depends on navigating the Q3 advanced-order reversal, completing ERP and HIS separation work, and containing tariff, inflation, and separation-related pressures.
Reported After market closeNYSEHealthcare
$15.38B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.55
Consensus $1.90
EPS surprise
+34.2%
Reported versus consensus
Reported revenue
$2.21B
Consensus $2.15B
Revenue surprise
+2.6%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-5.2%
Event window
SPY move
-0.2%
Same window
Abnormal move
-5.0%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
+11.4%
Up to 20 sessions
SOLVSPY benchmark
Ask FN2 about SOLV FY2026 Q2
Transcript, numbers and history already loaded
Why did SOLV fall 5.2% after beating EPS estimates in FY2026 Q2?What changed in SOLV's guidance and outlook in FY2026 Q2?Give me the bull and bear case for SOLV after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, management reported stronger Q2 execution, raised full-year organic-growth and EPS guidance, and moved the Health Information Systems separation forward. Acera continued to show strong growth, while the company disclosed a $125 million advanced-order benefit that will reverse in Q3.
Guidance delta
Management raised full-year EPS guidance to $7.10-$7.20 and organic sales growth guidance to 2.5%-3.0%, or 3.5%-4.0% excluding SKU rationalization.
Key takeaways
- Q2 revenue and EPS exceeded guidance, with 9.5% organic growth and EPS of $2.55.
- The 3M separation is in its final phases, while the Health Information Systems spin-off is moving forward.
- Acera grew more than 40% year over year with gross margin above 80%, supporting management's tuck-in acquisition strategy.
- A $125 million advanced-order benefit is expected to reverse in Q3, creating a near-term comparison risk.
- Management plans nearly 20 product launches by early 2028 and expects ERP progress to support future savings.
Management priorities
- Complete the final phases of the 3M separation and ERP transition.
- Advance the Health Information Systems separation and provide updates on its financial impact.
- Continue tuck-in acquisitions following the Acera playbook.
- Launch approximately 20 products by Q1 2028.
- Use ERP-related savings to fund growth initiatives and margin expansion.
Follow SOLV with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$88.84Previous close
$43Low
$85.1Average
$113High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Sep 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Sep 14, 2026 |
| Wedbush | Outperform | Outperform | Maintain | Aug 6, 2026 |
| UBS | Buy | Buy | Maintain | Aug 6, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 6, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | May 6, 2026 |
| Mizuho | Outperform | Neutral | Upgrade | Jan 20, 2026 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Jul 15, 2025 |
| Argus Research | Buy | Hold | Upgrade | Jul 1, 2025 |
| Goldman Sachs | Sell | Sell | Maintain | Mar 3, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Feb 26, 2025 |
Named analyst price targets
Upside is calculated against the persisted previous close $88.84. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Stifel Nicolaus | Analyst unavailable | $100 | $84.82 | +12.6% | Aug 6, 2026 |
| UBS | Patrick Wood | $101 | $87.47 | +13.7% | Aug 6, 2026 |
| Mizuho Securities | Analyst unavailable | $113 | $87.47 | +27.2% | Aug 6, 2026 |
| KeyBanc | Analyst unavailable | $102 | $87.47 | +14.8% | Aug 6, 2026 |
| BTIG | Ryan Zimmerman | $95 | $87.47 | +6.9% | Aug 6, 2026 |
| UBS | Analyst unavailable | $95 | $80.47 | +6.9% | Jul 28, 2026 |
| BTIG | Analyst unavailable | $91 | $76.7 | +2.4% | Jul 13, 2026 |
| BMO Capital | Analyst unavailable | $81 | $75.18 | -8.8% | Jul 8, 2026 |
| Jefferies | Analyst unavailable | $43 | $74.95 | -51.6% | Jun 1, 2026 |
| Wedbush | Michael Piccolo | $94 | $74.42 | +5.8% | May 15, 2026 |
| UBS | Kevin Caliendo | $78 | $71.36 | -12.2% | May 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $90 | $69.04 | +1.3% | May 6, 2026 |
| KeyBanc | Brett Fishbin | $93 | $69.04 | +4.7% | May 6, 2026 |
| KeyBanc | Brett Fishbin | $92 | $68.52 | +3.6% | Apr 27, 2026 |
| Piper Sandler | Analyst unavailable | $92 | $68.88 | +3.6% | Apr 17, 2026 |
| KeyBanc | Brett Fishbin | $97 | $78.91 | +9.2% | Jan 26, 2026 |
| Mizuho Securities | Analyst unavailable | $100 | $79.48 | +12.6% | Jan 20, 2026 |
| Stifel Nicolaus | Analyst unavailable | $105 | $83.16 | +18.2% | Jan 7, 2026 |
| BTIG | Ryan Zimmerman | $100 | $85.56 | +12.6% | Dec 2, 2025 |
| UBS | Kevin Caliendo | $77 | $73 | -13.3% | Oct 1, 2025 |
| Morgan Stanley | Patrick Wood | $103 | $73.68 | +15.9% | Jul 15, 2025 |
| Mizuho Securities | Analyst unavailable | $82 | $80.16 | -7.7% | Mar 3, 2025 |
| Wells Fargo | Analyst unavailable | $75 | $79.75 | -15.6% | Feb 28, 2025 |
| Mizuho Securities | Steven Valiquette | $70 | $72.28 | -21.2% | Dec 3, 2024 |
| Stifel Nicolaus | Rick Wise | $82 | $66.29 | -7.7% | Oct 7, 2024 |
| Piper Sandler | Jason Bednar | $71 | $67.74 | -20.1% | Oct 7, 2024 |
| Morgan Stanley | Patrick Wood | $55 | $49 | -38.1% | Jul 15, 2024 |
| Goldman Sachs | David Roman | $54 | $59.72 | -39.2% | May 30, 2024 |
| Morgan Stanley | Patrick Wood | $70 | $65.52 | -21.2% | Apr 9, 2024 |
| Wells Fargo | Vik Chopra | $69 | $70.06 | -22.3% | Apr 8, 2024 |
Track every rating change on SOLV the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSolventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes.…
Historical context
All SOLV earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
| A Agilent Technologies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +8.7% | +1.7% | Agilent raises outlook after Q3 beat; Ignite drives margin gains |
Latest beats and misses
Who reports nextBeat on EPS
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
- CASYFY2027 Q1 · September 8, 2026+8.7% EPS-14.2% move
Get the SOLV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-08-07T21:15:14.904053+00:00
- FN2 earnings calendar · 2026-09-10T01:23:13.706414+00:00
- Polygon adjusted daily market bars · 2026-09-22T08:00:53.968452+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-22T08:00:53.964389+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.